Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Not a good sign

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Jan 11, 2021 10:04am

154 Views

Post# 32266256

RE:RE:Not a good sign

Price hitting $4.10 early in the day so that's a start.

I'm trying to keep an open mind for the release, if you're deep into this then it didn't really move the needle much but if you put this in front of new institutional investors its still a compelling story.

Patience is key, I know we have all heard that before though...

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023